Eli Lilly and Company (LLY) pipeline and stated timing
Name in SEC filings: Eli Lilly and Company
No current calendar date is shown here. Retained program statements and source dates appear below.
Programs and stated timing
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
No source-verified calendar row is retained.
How this date was described over time
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
No additional verified wording history is retained.
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Retained company announcements
Historical summaries and source dates are retained separately from the SEC timing quotes above. Earlier publications were collected retrospectively.
Retained summary: Lilly expected the confirmatory TRAILBLAZER-ALZ 2 readout in Q2 2023. The announcement separately described a complete response letter for the earlier accelerated-approval application; those are different events.
Retained summary: Lilly announced Phase 3 topline results and reported meeting the primary endpoint. The release also described serious amyloid-related imaging abnormalities, including deaths; the readout is not a blanket safety claim.
These are selected linked records and dated source metadata, not a live registry recheck or the company’s full pipeline. Company announcements and the selected registry study are separate evidence sets. No stage or event timing is borrowed between them.
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.
Q1–Q4 (also written 1Q–4Q) are quarters of the year: Q1 is January–March, Q2 April–June, Q3 July–September and Q4 October–December, unless the company uses a different fiscal year.Topline results are the main summary results of a clinical trial, released before the full data.